|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013089,
umls-concept:C0023610,
umls-concept:C0027651,
umls-concept:C0043210,
umls-concept:C0178602,
umls-concept:C0201734,
umls-concept:C0208973,
umls-concept:C0243192,
umls-concept:C0658617,
umls-concept:C1517892,
umls-concept:C1704666
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-11-8
|
|
pubmed:abstractText |
Receptors for luteinizing hormone-releasing hormone (LHRH) can be utilized for targeted chemotherapy of cytotoxic LHRH analogs. The compound AEZS-108 (previously AN-152) consists of [D-Lys?]LHRH linked to doxorubicin. The objectives of this first study in humans with AESZ-108 were to determine the maximum tolerated dose and to characterize the dose-limiting toxicity, pharmacokinetics, preliminary efficacy, and hormonal effects.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1095-6859
|
|
pubmed:author |
pubmed-author:EmonsGünterG,
pubmed-author:EngelJürgenJ,
pubmed-author:GünthertAndreas RAR,
pubmed-author:GorchevGrigorG,
pubmed-author:GründkerCarstenC,
pubmed-author:HankerLars CLC,
pubmed-author:KaufmannManfredM,
pubmed-author:SchallyAndrew VAV,
pubmed-author:SindermannHerbertH,
pubmed-author:TsekovaValentinaV,
pubmed-author:VelikovaMayaM
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
119
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
457-61
|
|
pubmed:meshHeading |
pubmed-meshheading:20828803-Antibiotics, Antineoplastic,
pubmed-meshheading:20828803-Breast Neoplasms,
pubmed-meshheading:20828803-Dose-Response Relationship, Drug,
pubmed-meshheading:20828803-Doxorubicin,
pubmed-meshheading:20828803-Endometrial Neoplasms,
pubmed-meshheading:20828803-Female,
pubmed-meshheading:20828803-Gonadotropin-Releasing Hormone,
pubmed-meshheading:20828803-Humans,
pubmed-meshheading:20828803-Hydrocortisone,
pubmed-meshheading:20828803-Maximum Tolerated Dose,
pubmed-meshheading:20828803-Middle Aged,
pubmed-meshheading:20828803-Ovarian Neoplasms,
pubmed-meshheading:20828803-Pituitary Gland,
pubmed-meshheading:20828803-Receptors, LHRH
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors.
|
|
pubmed:affiliation |
University Clinic Göttingen, Göttingen, Germany. Emons@med.uni-goettingen.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
